TODAY -

Transforming hope into reality for patients of drug-resistant TB

Shobha Shukla *



Multidrug-resistant TB (MDR-TB) remains a public health crisis. As per WHO's Global TB Report 2016, 480,000 people fell ill with MDR-TB in 2015, with 3 countries – India, China, and Russia – carrying the major burden and together accounting for nearly half of all MDR-TB cases globally.

Detection and treatment gaps continue to plague the MDR-TB response. In 2015, only 1 out of every 5 people needing treatment for MDR-TB were able to access it and only 52% of those who started MDR-TB treatment were cured.

"These sobering statistics remind us of our urgency to continue the fight to develop better, faster and affordable treatments that will finally bring this pandemic under control," said Dr Mel Spigelman, CEO of TB Alliance, which is working to advance several promising regimens to tackle all forms of TB.

The current MDR-TB regimen lasts for 2 years or more. It includes medicines and injectables that are not only toxic but also come at a cost that is higher than what many patients and healthcare systems can afford. Even the new 9 month MDR-TB regimen that has recently been endorsed by WHO, though shorter, does include 4 months of injectables.

However new results from 2 clinical studies conducted by TB Alliance point to an emerging paradigm, where countries may soon have the short, all-oral, and affordable drug regimens needed to treat all people with TB. Late stage clinical results from these two studies were unveiled yesterday at the 47th Union World Conference on Lung Health in Liverpool.

The NC-005 study

The NC-005 study investigates an oral, injection free regimen that purports to treat both drug-sensitive and MDR-TB with a short, simple, safe, and affordable treatment. A Phase 2b, 2 month study tested various combinations of BPaMZ—Bedaquiline (B), Pretomanid (Pa), Moxifloxacin (M) and Pyrazinamide (Z). It was conducted at 10 sites in 3 countries (Uganda, South Africa, and Tanzania).

A total of 240 patients were enrolled in the study— 180 patients with drug-sensitive TB received BPaZ and 60 patients with MDR-TB received BPaMZ. The study also investigated a simpler dosing scheme for bedaquiline, which could lead to fewer pills and an overall less complicated treatment for patients.

NC-005 showed that the best regimen was a combination of all four drugs, BPaMZ, which was examined in an arm of the trial. Data showed that at the end of 2 months, clinical study participants receiving BPaMZ cleared TB bacteria from their sputum 3 times as quickly as those on the standard treatment regimen. Almost all participants had culture conversion after the 2 months of treatment.

This is the fastest rate of culture conversion that has ever been seen and indicates the potential of BPaMZ to treat all forms of TB-drug-sensitive as well as MDR-TB with the same regimen. The regimens appeared safe. The study showed that it was possible to simplify the dosing of Bedaquiline and found that a daily dose of Bedaquiline (200 mg) is at least as active and safe as the labelled dose. This will allow for simpler daily dosing with the regimen and to be combined in a fixed dose combination.

The BPaMZ regimen is being tested to see if it can cure the vast majority of TB patients in as less as 3 months. If successful, the regimen could reshape the treatment landscape of TB, especially for people with MDR-TB, who currently face an arduous 9-24 month treatment journey that is too often unsuccessful. The results of NC-005 could pave the way to a global Phase 3 trial.

The Nix-TB Study
('Nix' means to put an end to)

It is estimated that 9% of all the MDR-TB patients suffer from extensively drug-resistant TB (XDR-TB) that is resistant to at least four commonly used anti-TB drugs. XDR-TB is often considered a death sentence. Most XDR-TB is not treated at all because of the cost and complexity of the treatment. Of those who do receive treatment, less than one third get cured.

In May 2015, TB Alliance and partners launched the world's first clinical study— the Nix-TB Study-to test a new XDR-TB drug regimen called BPaL, consisting of Bedaquiline (B), Pretomanid (Pa), and Linezolid (L) in patients who have no other treatment options. It is the first study to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, that has the potential to shorten, simplify, and improve treatment for XDR-TB.

Nix-TB is an open-label study that is being conducted at 2 sites in South Africa—at Sizwe Hospital in Johannesburg and at Brooklyn Chest Hospital in Cape Town. Additional sites to expand the study are planned.

Patients who have XDR-TB, or have failed their current MDR-TB treatment or who have side effects of their current MDR-TB treatment, are enrolled.Till to date, 50 patients have been enrolled in the study, including patients as young as 14 and those who are co-infected with HIV with a CD4 cell count of 50 or higher.

Initial data from the study shows the promise of BPaL to treat XDR-TB in only 6 months – Bedaquiline (400 mg daily for 2 weeks followed by 200 mg twice a week), Pretomanid (200 mg daily) and Linezolid (1200 mg daily) given orally for 6 months with the option to extend treatment to 9 months for participants who do not culture convert within 4 months. Patients are assessed at regular intervals with the aim of being cured in 6 months. After completing treatment, participants will be monitored for two years to ensure they do not relapse.

The interim results (between April 2015 and July 2016) on the first 15 participants enrolled in the study, of whom 7 were HIV positive, showed that 12 of them completed 6 months of therapy. The majority were culture negative by week 8 and no patient needed an extension of treatment. As of July 1, 2016 there have been no clinical or micro biological relapses.

As of now, 30 patients have completed 6 months of treatment and all have negative cultures of their sputum. There have been no relapses to date, although the study is still ongoing. The rest of the patients are in various stages of treatment and follow-up. 4 patients have died, but this is a substantially lower mortality than ever reported before.

The early results of this greatly simplified and shortened all oral regimen for XDR-TB appear to be encouraging in terms of both efficacy and safety. The regimen appears safe but requires medical supervision. Linezolid, which has been used off-label to treat MDR-TB, has considerable toxicity but was managed in a clinical study setting.

This is the first injection-free regimen for XDR-TB that, if successful, could transform XDR-TB treatment, with patients being cured by taking a relatively short, simple, oral and effective regimen. Importantly, the regimen would also reduce the complexity and cost of the treatment to a fraction of what it is today, facilitating the global implementation of XDR-TB treatment in resource-poor nations.

These regimens can be deployed in the context of currently available or forthcoming diagnostics. These regimens may revolutionise and markedly reshape the treatment landscape for TB by offering a common therapy for virtually all people with drug-sensitive and drug-resistant TB, and a closely related treatment for those with extensively drug-resistant TB.


* Shobha Shukla (Citizen News Service (CNS)) wrote this article for e-pao.net
Shobha Shukla is providing thematic coverage from the 47th Union World Conference on Lung Health, Liverpool, United Kingdom, with kind support from TB Alliance (Global Alliance for TB Drug Development). Follow her on Twitter @Shobha1Shukla
This article was posted on November 02, 2016.


* Comments posted by users in this discussion thread and other parts of this site are opinions of the individuals posting them (whose user ID is displayed alongside) and not the views of e-pao.net. We strongly recommend that users exercise responsibility, sensitivity and caution over language while writing your opinions which will be seen and read by other users. Please read a complete Guideline on using comments on this website.




LATEST IN E-PAO.NET
  • Nongpok Sanjenbam village #1: Gallery
  • Chaklam Khongchat Numit #4: Gallery
  • Ways of seeing Atiyagi Maya
  • National Lok Adalat at Lamphel Court
  • Take Me Home :: Poem
  • Money Lending business in Nagaland
  • Ambeshori : Gold at Jr Women Natl Boxing
  • Crime against nature deserve punishment
  • Khamba Thoibi Museum #1 : Gallery
  • Time- Is it an illusion? Certainly not
  • Can there really be peace without justice
  • Enrollment Program for PMJAY & CMHT
  • Heavy traffic fines, Harekrishna krishna
  • Jenil Khuman : Heroes of India award
  • Cracking the whip on driving by minors
  • ST demand: Is this a consensus decision..
  • Mukna - indigenous game : Gallery
  • Leikoiba, Lanhim, Khangjenlu :: eMing
  • An interaction with Dr. O.K. Singh #1
  • Cry of a Dying River - 92 :: Poem
  • Missing person : Dongminlian at Tirupati
  • Google Earth for ground & aerial survey
  • Mary Kom 1st woman athlete for Vibhushan
  • The Killing Fields 2013-18 : News Timeline
  • Delivering a point maturely
  • There should be a toll free grievance cell
  • Hiyang Tanaba @Lamlai #1: Gallery
  • Shrinking safe spaces
  • Child sexual abuse (CSA)
  • Demands: Flag for Naga & ST for Meitei
  • Proud of our scientists & ISRO
  • Daanveer Dutta Karna : 2nd best play
  • Inner Line Permit (ILP) Demand :: Timeline
  • Significance of Sept 11 to TSE
  • Climate Crisis, People, and the State
  • Ibudhou Marongkhong Haraoba #3: Gallery
  • Conundrum for Manipur govt over CAB
  • Violence against medical fraternity
  • Thongkhatabam Ankita : Governor's Award
  • The Enchantress :: Poem
  • Sunyata & Kenosis: Search of Ultimate Truth
  • Lim divide continues to run deep
  • Of nationalism, patriotism & against nature
  • Heikru Hidongba #1 : Gallery
  • Komrem Students Day @B'lore : Gallery
  • Protective Thinking: Village Nationalist #1
  • Haipou Jadonang: A Social reformer #3
  • Ungracious :: Poem
  • Naga Peace Process :: News Timeline
  • IAS Officer: Hero- Whipping boy- Villain
  • Petition CM to revoke breach order in Edn-S
  • Stand against illegal immigrants
  • September and Hijam Irabot
  • Impact of Christianity among Vaiphei #3
  • Kakching WW II Memorial Run : Gallery
  • Framework Agreement: Divide the state
  • Training Program for Remand Advocates
  • Hunt for North East designers & models
  • Kakching World War II Memorial Run: Report
  • Common Admission Test for IIMs
  • No school bags day for young students
  • GoI backtracking on Framework Agreement
  • Trekking to Dzukou #3 : Gallery
  • English as a Lingua Franca for NE
  • A Good Place to Spend the Night : Poem
  • The idea of Manipur
  • Vacancies at Hadron Techs, Imphal
  • 8th Convocation of Assam Don Bosco held
  • Yogurt based DIY packs to try
  • Big Bang Edge Test
  • Bhabananda was right; it was not only him ..
  • Chaklam Khongchat Numit #3: Gallery
  • Judicial administration under Bhagyachandra
  • Reena Bhavsar(Pebam ningon): Mrs India
  • Sick Education System should be blamed ...
  • Foundation Day of Physics Dept, MU
  • 26th World Congress of Political Science
  • DBC, Maram bags SBSI National award
  • Regulate pay of Pvt school teachers
  • Chingda Satpi Engellei #1 : eRang
  • The Endurers : a growing tribe
  • Swachh in Manipur
  • Khongoinaba & Kanglei Chanura Kanba
  • The ten in between :: Poem
  • Happy for no reason
  • Convocation: Assam Don Bosco University
  • Sounding the alert at the entry points:
  • Victims of greed
  • Folk Dance @Retreat ceremony #2: Gallery
  • Call for Papers : NACETER 2019 at Aizawl
  • Celebrating Teachers' Day 2019
  • Draft Bill on violence against healthcare
  • From the heart - Transcending fears
  • Her Richness :: Poem
  • Beauty benefits of mint
  • Return of the power struggle
  • 'We Dont, So Shouldnt You' of Mayangs
  • Licypriya: Peace Prize : Gallery
  • Haipou Jadonang: A Social reformer #2
  • Licypriya : World Children Peace Prize
  • Champions at 5th Intl Thang-Ta C'ship
  • International Geological Congress 2020
  • Manipur Tourism: Best cultural Award at TTF
  • 46th AMWJU Foundation Day
  • NDPP leaders called on Nagaland Governor
  • Condemns UP Govt for case against Journo
  • Looking to CBI to deliver: The trust deficit
  • Mockery of the legislation
  • Hinduism in Manipur # 2
  • No mee should disturb peace in Kuki Hills
  • Cry of a Dying River - 91 :: Poem
  • Human service demands need to save river
  • Aromatherapy as career option
  • Khelen Thokchom Media Fellowship
  • Rejoinder to Yanthungo Patton
  • New traffic rules and regulations
  • Myopic leaders and misplaced priorities
  • Over 19 lakhs excluded in Assam NRC
  • Chaklam Khongchat Numit #2: Gallery
  • Sangai Fest: Maibi Jagoi : Gallery
  • FMGE -Foreign Medical Graduates Exam
  • Referendum in Catalonia
  • Allergen-specific blood test for allergies
  • Better investment climate: Challenge of Govt
  • AMWJU Identity Card
  • Chayom Thupki (Meetei Philosophy) #10
  • September Calendar for Year 2019 : Tools
  • Freshers Meet/Musical Night at Bangalore
  • Surgery over Healthcare
  • Discussion: Identity at India-Myanmar Border
  • A Euphoric Day Of Freedom :: Poem
  • Remembering the past famine...
  • Stalls- Hathei Phanit, Ukhrul #1: Gallery
  • AMSU & Naga Peace Talk
  • Hypocrisy of 'The Federation Of Haomee'
  • Introspecting renewed Hydropower push #2
  • Enrolment Program for PMJAY & CMHT
  • Nourishing homemade body wash
  • FIT India Movement Launch at ADBU
  • Deadline to ban one time use plastics
  • An opportunity to turn back nature
  • Martyrdom of Haipou Jadonang: Gallery
  • The traffic maze
  • Haipou Jadonang: A Social reformer #1
  • Chinglensana Kangujam : Arjuna Award
  • A Rainy Morning in Summer :: Poem
  • Background of NRC (Assam) Act 1950
  • The name : Arguments over BT Airport
  • The changing face of Manipuri Women
  • Apple Farmer Mayengbam Shyamchandra
  • Haipou Jadonang Marangmei- The Martyr
  • Tourism & its new insights- Geotourism
  • Assam newspaper: From Arunodoi ...
  • The idea of a book club Imphal
  • Condemns act of locals in ICFAI Univ
  • Free medical camp at Ithai Barrage
  • Attacker on Childline must be arrested
  • Computer Courses at IP Infotech
  • Dead men or dead girls tell no tale
  • Going beyond people's expectations
  • Chaklam Khongchat Numit #1: Gallery
  • Wainu Chara : An indigenous rice breed
  • The sugarcane crisis
  • Positive Teachers-Students relation
  • NDPP & BJP met with Bishop of Nagaland
  • Zero budget natural farming
  • Helmet drive with sweets at CCpur
  • Responsibility matters
  • Manipur Independence Day : Gallery
  • Manipur Heli Service : Gallery
  • Kariang nuna sip eh :: Poem
  • River Rights as legal person
  • Athokpam Right: Kalams Book of Record
  • Be Educated; Be Empowered 0.02 Edition
  • Separate flag and separate Constitution
  • Manipur on a high: Drug menace
  • Impact of Christianity among Vaiphei #2
  • Introspecting renewed Hydropower push #1
  • Jhulon @ Imphal #2 : Gallery
  • Climate variability in Phalee khul, Ukhrul
  • What vows does a catholic priest take ?
  • Leg Pain : What to do ?
  • Convention: Defense of Democratic Rights
  • Transit route to manufacturing unit
  • Khangkhui Cave, Ukhrul #5 : Gallery
  • Meeting on Road project at Phalong
  • The road that halted us by earthfall
  • National Entrepreneurship Awards 2019
  • Strategies to adopt for IAS Exam
  • Discussion: Issues of Legal Services
  • Irregularities of Non-NET Fellowship in MU
  • Threatened democracy
  • Nagas await historic day: NSCN (I-M)
  • Hathei Phanit @Ukhrul #1 : Gallery
  • Stunted Agriculture: policy failure
  • Kashmir Lockdown & its Implications
  • Dr Ak Priyokumar : Golden Achiever Award
  • Amazing beauty benefits of sea salt
  • Women entrepreneurship program in NE
  • Critically endangered species : Pony
  • Rescue for the degrading environment
  • Hinduism in Manipur # 1
  • Foundation of School Fagathansi Mission
  • Healing Leadership- Need of the Hour
  • Shri Krishna Janmasthami :: Book
  • Police : A friend or a foe ?
  • Cry of a Dying River - 90 :: Poem
  • King Leishemba attended HUNIC, Thailand
  • MBA in Global Supply Chain Management
  • Significance of Aug to NSCN (IM)
  • Restoring public education system
  • Lai-Harouba @JNMDA #2 : Gallery
  • Sangai fest: Dance Drama : Gallery
  • Our Destiny Lies Only In Our Unity
  • Hanging : Suicide or homicide ?
  • Trainees from Ukhrul selected as Air Crew
  • NPF met with Nagaland Governor
  • NH7 Weekender Artists for Meghalaya
  • NH7 Weekender Artists for Pune
  • Studying how schools are run
  • Nature- the answer to global warming
  • N'Jang-Ngi Thangal fest : Gallery
  • TB is preventable & curable
  • Fake :: Poem
  • Pradhan Mantriji's 'Leirum Lengyan'
  • B Voc / M Voc courses at DM College
  • Awareness Program on Child Rights
  • Mountain Echoes, Bhutan Festival
  • Ambeshori : Gold at Nation's Cup, Serbia
  • Th Muivah : Man in the news
  • Doctors: scapegoats of a faulty system
  • Jhulon @ Nabadwip, WB : Gallery
  • School Fagathanshi Mission : Gallery
  • GojiLove : Top 20 biggest startup of India
  • Manju & Aneshori : Bismillah Award 2018
  • Healthy & active lifestyle: A healthy Manipur
  • Heikat-Leikat [13 Aug] #2 : Gallery
  • 13 August: Day to remember the heroes #2
  • Lukanand Ksh & Langpoklakpam Melody
  • IIT Guwahati's half marathon
  • Getting the best out of Govt schools
  • Babysana: Student - Aug 10 #2: Gallery
  • Jhulon @ Imphal #1 : Gallery
  • Eyek Tamba :: Learn Manipuri script
  • Chayom Thupki (Meetei Philosophy) #9
  • Indigeneity: Expression & Experience : Book
  • Patriots' Day @ Pune : Gallery
  • Babysana: State bandh - Aug 9 #2: Gallery
  • Babysana: Student protest- Aug 8: Gallery
  • Folklore of Hao communities #3
  • Aliyah #2 (Film Scenes) :: eRang
  • Kanglen Kang Chingba #2 : Gallery
  • Babysana's last rites performed: Gallery
  • Featured Front Page Photo 2019 #3: Gallery
  • Tolloi, Ukhrul :: 360 Panorama View
  • Manipuri Calendar for 2019 : Download
  • SPONSORED ADS